JP2002529097A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2002529097A5 JP2002529097A5 JP2000581225A JP2000581225A JP2002529097A5 JP 2002529097 A5 JP2002529097 A5 JP 2002529097A5 JP 2000581225 A JP2000581225 A JP 2000581225A JP 2000581225 A JP2000581225 A JP 2000581225A JP 2002529097 A5 JP2002529097 A5 JP 2002529097A5
- Authority
- JP
- Japan
- Prior art keywords
- tumor
- compound
- product
- medicament
- medicine
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000003814 drug Substances 0.000 description 7
- 238000000034 method Methods 0.000 description 7
- 206010028980 Neoplasm Diseases 0.000 description 6
- 150000001875 compounds Chemical class 0.000 description 5
- 208000003174 Brain Neoplasms Diseases 0.000 description 3
- 108020004440 Thymidine kinase Proteins 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N glycerol group Chemical group OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 231100000433 cytotoxic Toxicity 0.000 description 2
- 230000001472 cytotoxic effect Effects 0.000 description 2
- IRSCQMHQWWYFCW-UHFFFAOYSA-N ganciclovir Chemical compound O=C1NC(N)=NC2=C1N=CN2COC(CO)CO IRSCQMHQWWYFCW-UHFFFAOYSA-N 0.000 description 2
- 229960002963 ganciclovir Drugs 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 239000003381 stabilizer Substances 0.000 description 2
- 241000701161 unidentified adenovirus Species 0.000 description 2
- 241000976806 Genea <ascomycete fungus> Species 0.000 description 1
- 241000700584 Simplexvirus Species 0.000 description 1
- 102000006601 Thymidine Kinase Human genes 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB9824437.9A GB9824437D0 (en) | 1998-11-06 | 1998-11-06 | Gene therapy |
| GB9824437.9 | 1998-11-06 | ||
| PCT/EP1999/009017 WO2000028059A1 (en) | 1998-11-06 | 1999-11-05 | Adenovirus-mediated gene therapy |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2002529097A JP2002529097A (ja) | 2002-09-10 |
| JP2002529097A5 true JP2002529097A5 (cg-RX-API-DMAC7.html) | 2006-12-21 |
| JP4733833B2 JP4733833B2 (ja) | 2011-07-27 |
Family
ID=10842035
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2000581225A Expired - Fee Related JP4733833B2 (ja) | 1998-11-06 | 1999-11-05 | アデノウィルスを介する遺伝子治療 |
Country Status (18)
| Country | Link |
|---|---|
| US (1) | US6579855B1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP1135513B2 (cg-RX-API-DMAC7.html) |
| JP (1) | JP4733833B2 (cg-RX-API-DMAC7.html) |
| KR (1) | KR20020013473A (cg-RX-API-DMAC7.html) |
| CN (1) | CN1184321C (cg-RX-API-DMAC7.html) |
| AT (1) | ATE341639T1 (cg-RX-API-DMAC7.html) |
| AU (1) | AU749451B2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA2348624C (cg-RX-API-DMAC7.html) |
| CY (1) | CY1106198T1 (cg-RX-API-DMAC7.html) |
| DE (1) | DE69933468T3 (cg-RX-API-DMAC7.html) |
| DK (1) | DK1135513T4 (cg-RX-API-DMAC7.html) |
| ES (1) | ES2273521T5 (cg-RX-API-DMAC7.html) |
| GB (1) | GB9824437D0 (cg-RX-API-DMAC7.html) |
| HU (1) | HUP0104046A3 (cg-RX-API-DMAC7.html) |
| NO (1) | NO330776B1 (cg-RX-API-DMAC7.html) |
| PL (1) | PL193076B1 (cg-RX-API-DMAC7.html) |
| PT (1) | PT1135513E (cg-RX-API-DMAC7.html) |
| WO (1) | WO2000028059A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0910950D0 (en) | 2009-06-24 | 2009-08-05 | Ark Therapeutics Ltd | Filtration |
| GB0916997D0 (en) * | 2009-09-28 | 2009-11-11 | Ark Therapeutics Ltd | Combination therapy |
| US20130296407A1 (en) * | 2011-01-18 | 2013-11-07 | Ark Therapeutics, Ltd. | Combination Therapy for Cancer |
| GB201100804D0 (en) * | 2011-01-18 | 2011-03-02 | Ark Therapeutics Ltd | Drug combination |
| SG10201604810UA (en) | 2012-02-07 | 2016-08-30 | Global Bio Therapeutics Inc | Compartmentalized method of nucleic acid delivery and compositions and uses thereof |
| US20160058888A1 (en) * | 2013-05-08 | 2016-03-03 | Gliotherapy Limited | Treatment of Operable High-Grade Glioma With Sitimagene Ceradenovec Gene Therapy and Ganciclovir |
| CN105813579B (zh) | 2013-08-08 | 2019-05-07 | 全球生物疗法有限公司 | 用于微创手术过程的夹具装置和其应用 |
| DE102019000490A1 (de) | 2019-01-23 | 2020-07-23 | HAEMES Verwaltungsgesellschaft mbH | Verwendung von Oligonukleotiden für die Behandlung von Tumoren |
| IL293978A (en) | 2019-12-20 | 2022-08-01 | Regeneron Pharma | New il2 agonists and methods of using them |
| KR20230009430A (ko) | 2020-05-12 | 2023-01-17 | 리제너론 파아마슈티컬스, 인크. | 신규 il10 효능제 및 그의 사용 방법 |
| CN117597365A (zh) | 2021-05-04 | 2024-02-23 | 再生元制药公司 | 多特异性fgf21受体激动剂及其应用 |
| AU2022314734A1 (en) | 2021-07-19 | 2024-02-08 | Regeneron Pharmaceuticals, Inc. | Il12 receptor agonists and methods of use thereof |
| US12559576B2 (en) | 2021-11-11 | 2026-02-24 | Regeneron Pharmaceuticals, Inc. | CD20-PD1 binding molecules and methods of use thereof |
| AU2024207005A1 (en) | 2023-01-13 | 2025-08-28 | Regeneron Pharmaceuticals, Inc. | Il12 receptor agonists and methods of use thereof |
| CN121002062A (zh) | 2023-01-13 | 2025-11-21 | 再生元制药公司 | Fgfr3结合分子及其使用方法 |
| IL322890A (en) | 2023-02-28 | 2025-10-01 | Regeneron Pharma | Multispecific molecules containing an MHC-peptide complex containing an MHC domain and an antigenic peptide and a partially targeted immune cell antigen |
| WO2024233926A1 (en) | 2023-05-10 | 2024-11-14 | Regeneron Pharmaceuticals, Inc. | Cd20-pd1 binding molecules and methods of use thereof |
| KR20260113057A (ko) | 2023-11-14 | 2026-07-21 | 리제너론 파아마슈티컬스, 인크. | 조작된 중쇄 가변 도메인 및 이의 용도 |
| WO2025240335A1 (en) | 2024-05-13 | 2025-11-20 | Regeneron Pharmaceuticals, Inc. | Fgfr3 binding molecules and methods of use thereof |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH0662441B2 (ja) * | 1986-02-18 | 1994-08-17 | 花王株式会社 | 抗腫瘍物質徐放性製剤 |
| US5631236A (en) * | 1993-08-26 | 1997-05-20 | Baylor College Of Medicine | Gene therapy for solid tumors, using a DNA sequence encoding HSV-Tk or VZV-Tk |
-
1998
- 1998-11-06 GB GBGB9824437.9A patent/GB9824437D0/en not_active Ceased
-
1999
- 1999-11-05 HU HU0104046A patent/HUP0104046A3/hu not_active Application Discontinuation
- 1999-11-05 JP JP2000581225A patent/JP4733833B2/ja not_active Expired - Fee Related
- 1999-11-05 PL PL349489A patent/PL193076B1/pl unknown
- 1999-11-05 PT PT99971860T patent/PT1135513E/pt unknown
- 1999-11-05 EP EP99971860A patent/EP1135513B2/en not_active Expired - Lifetime
- 1999-11-05 WO PCT/EP1999/009017 patent/WO2000028059A1/en not_active Ceased
- 1999-11-05 DE DE69933468T patent/DE69933468T3/de not_active Expired - Lifetime
- 1999-11-05 US US09/830,725 patent/US6579855B1/en not_active Expired - Lifetime
- 1999-11-05 KR KR1020017004945A patent/KR20020013473A/ko not_active Ceased
- 1999-11-05 CN CNB998129305A patent/CN1184321C/zh not_active Expired - Fee Related
- 1999-11-05 DK DK99971860.4T patent/DK1135513T4/da active
- 1999-11-05 AT AT99971860T patent/ATE341639T1/de active
- 1999-11-05 AU AU13851/00A patent/AU749451B2/en not_active Ceased
- 1999-11-05 ES ES99971860T patent/ES2273521T5/es not_active Expired - Lifetime
- 1999-11-05 CA CA2348624A patent/CA2348624C/en not_active Expired - Fee Related
-
2001
- 2001-05-04 NO NO20012220A patent/NO330776B1/no not_active IP Right Cessation
-
2006
- 2006-10-13 CY CY20061101473T patent/CY1106198T1/el unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA2348624A1 (en) | Adenovirus-mediated gene therapy | |
| MY124853A (en) | 4-amino-5-phenyl-7-cyclobutyl-pyrrolo[2,3-d]pyrimidine derivatives. | |
| DE69533128D1 (de) | Pharmazeutische akzeptabel dnase zusammensetzung | |
| US8771663B2 (en) | Formulation having mobilising activity | |
| CY1105707T1 (el) | Συνδυασμοι φορμοτερολης και ενος αλατος τριοτροπιου | |
| WO2000053730A3 (en) | Medical preparations for the treatment of alpha-galactosidase a deficiency | |
| WO2002045431A3 (en) | Genetically engineered herpes virus for the treatment of cardiovascular disease | |
| JP2002532432A5 (cg-RX-API-DMAC7.html) | ||
| BR9807319A (pt) | Microgrânulos com liberação controlada, para administração oral, contendo cisplatina, processo de preparação dos mesmos, preparação farmacêutica, e, utilização dos microgrânulos. | |
| WO1998000541A3 (en) | Methods for administration of recombinant gene delivery vehicles for treatment of human disease | |
| RU97104483A (ru) | Соль янтарной кислоты 4-[2-амино-6-(циклопропиламино)-9н-пурин-9-ил]-2- циклопентен-1-метанола в качестве антивирусного агента | |
| JP2002530353A5 (cg-RX-API-DMAC7.html) | ||
| Soria et al. | Effect of food on the pharmacokinetics and bioavailability of oral imiquimod relative to a subcutaneous dose | |
| JP2003534282A5 (cg-RX-API-DMAC7.html) | ||
| WO2003084979A3 (fr) | Peptides et leur application en therapeutique | |
| US20170348345A1 (en) | Combination Therapy For Cancer | |
| WO2006127938A1 (en) | Methods and compositions using 4[(cyclopropanecarbonylamino)methyl]-2-(2,6-dioxopiperridin-3yl) isoindole-1,3-dione for the treatment of prevention of cutaneous lupus | |
| Suntsova et al. | Use of romiplostim for newly diagnosed immune thrombocytopenia in children | |
| AR004196A1 (es) | Un metodo a alta velocidad para preparar granulos esfericos que comprende un medicamento para uso farmaceutico, granulos obtenibles mediante este metodoy una bolsita que contiene dichos granulos | |
| ZA202304877B (en) | Recombinant adeno-associated viruses with enhanced liver tropism and uses thereof | |
| JP2005502690A5 (cg-RX-API-DMAC7.html) | ||
| US7671038B1 (en) | Method of therapeautic treatments including human immunodeficiency virus (HIV) disease and other conditions in a human host by administering adenine nucleotides | |
| van der Veen et al. | Stealth® liposomal tumor necrosis factor-α in solid tumor treatment | |
| JP2002529515A5 (cg-RX-API-DMAC7.html) | ||
| JPH0551565B2 (cg-RX-API-DMAC7.html) |